Randomized Controlled Trial to Investigate Clinical Outcomes and Associated Costs When PermeaDerm is Used as Temporary Dressing for Surgical Wounds

Eligibility Criteria

• 1. The patient's wound requires temporary dressing coverage after surgical excision and prior to autografting.
• 2. The patient has a surgical wound up to 30% (inclusive) total body surface area (TBSA).
• 3. The study area is a contiguous area. If the patient has other areas (non-study treatment area) that require temporary dressing, these areas must also be dressed according to the randomization.
• 4. The patient is hospitalized within 3 days of injury.
• 5. The surgical excision occurs within 5 days post-injury.
• 6. The patient (or parent/guardian/legally authorized representative) is willing and able to comply with all study procedures and visit schedule.
• 7. The patient (or parent/guardian/legally authorized representative) agrees to abstain from any other treatment of the study area or enrollment in another interventional clinical trial for the duration of his/her participation in the study (8 weeks post-autografting).
• 8. In the opinion of the investigator, the patient (or parent/guardian/legally authorized representative) must be able to:
• 1. Understand the full nature and purpose of the study, including possible risks and adverse events,
• 2. Understand instructions, and
• 3. Provide voluntary written informed consent.
• 1. The study area has received prior surgical intervention.
• 2. The patient is currently using medications or treatments such as systemic corticosteroids, chemotherapy, or immunosuppressants, that in the investigator's opinion may compromise patient safety or trial objectives.
• 3. Clinical signs of wound infection at study area that in the investigator's opinion may compromise patient safety or trial objectives.
• 4. The patient has any of the following
• 1. morbid obesity (BMI \>40),
• 2. immunodeficiency,
• 3. venous insufficiency/PVD of the lower extremities (when study area is also in this location),
• 4. chronic malnourishment,
• 5. inhalation injury,
• 6. current abuser of alcohol and/or illicit drugs based upon medical history and/or lab results,
• 7. diabetes mellitus with HbA1c \>9.0%, and/or
• 8. advanced renal disease (eGFR \<59) or liver disease (LFTs \>2.5 times the upper limit).
• 5. The patient has any another condition, that in the investigator's opinion may compromise patient safety or the trial objectives.
• 6. The patient is pregnant (a pregnancy test is to be performed in accordance with local institutional requirements).
• 7. The patient is unable to understand English or Spanish.
• 8. The patient has a known hypersensitivity to bovine-derived collagen materials, porcine, aloe vera materials, or contraindications to the frozen human cadaveric allograft.
• 9. The patient's life expectancy is less than 1 year.